Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, Chen J, Huang G, Zhang P, Cheng Y, Liu J, Liu J, Zhang J, Wu D, Chen Y, Ma X, Pan H, Jiang R, Liu X, Ren X, Tian H, Jia Z, Guo J, Si L. Wei X, et al. Among authors: zhang p, zhang w, zhang j, zhang x. Eur J Cancer. 2024 May;202:114008. doi: 10.1016/j.ejca.2024.114008. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38479118 Clinical Trial.
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Yue D, et al. Among authors: zhang l, zhang p. Lancet Respir Med. 2024 Nov 21:S2213-2600(24)00269-8. doi: 10.1016/S2213-2600(24)00269-8. Online ahead of print. Lancet Respir Med. 2024. PMID: 39581197
Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study.
Deng Y, Hu H, Jia R, Dai W, Wang D, Zhang P, Zhang P, Cheng K, Tang J, Wen Y, Zhou X, Shi Q, Xiong Z, Zhou J. Deng Y, et al. Among authors: zhang p. BMC Pulm Med. 2023 May 19;23(1):176. doi: 10.1186/s12890-023-02432-5. BMC Pulm Med. 2023. PMID: 37208661 Free PMC article.
Comparing Real-World Outcomes of Catheter-Directed Thrombolysis and Catheter-Based Thrombectomy in Acute Pulmonary Embolism: A Post PEERLESS Analysis.
Zhang RS, Zhang P, Yuriditsky E, Taslakian B, Rhee AJ, Greco AA, Elbaum L, Mukherjee V, Postelnicu R, Amoroso NE, Maldonado TS, Alviar CL, Horowitz JM, Bangalore S. Zhang RS, et al. Among authors: zhang p. Catheter Cardiovasc Interv. 2024 Dec 26. doi: 10.1002/ccd.31386. Online ahead of print. Catheter Cardiovasc Interv. 2024. PMID: 39726241
31,376 results
You have reached the last available page of results. Please see the User Guide for more information.